Huntington’s disease research news. In plain language. Written by scientists. For the global HD community.

Are you looking for our logo? You can download our logo and get information about how to use it on our sharing page

Articles with the topic: featured

Switching it up: variety in the HD gene affects symptom onset

Switching it up: variety in the HD gene affects symptom onset

Melissa Christianson on May 29, 2015

Just like it is difficult to predict exactly when a storm will hit, predicting when Huntington’s disease symptoms will arise for any particular person is hard to do. However, new research suggests that tiny changes in the on switch of the Huntington’s gene affect symptom onset – and may provide important information in the search for Huntington’s therapies.

Positive results announced for re-worked tetrabenazine drug in Huntington's disease

Positive results announced for re-worked tetrabenazine drug in Huntington's disease

Dr Jeff Carroll on December 22, 2014

Auspex Pharmaceuticals just announced the results of two clinical trials known as 'First-HD' and 'Arc-HD'. These trials were designed to test a modified version of the approved Huntington's disease drug tetrabenazine, which reduces unwanted movements. The results reveal that Auspex's drug has some advantages compared to tetrabenazine for treating excessive movements in HD.

Huntington's disease clinical trial announcement: huntingtin-lowering drug to enter Phase I trial in 2015

Huntington's disease clinical trial announcement: huntingtin-lowering drug to enter Phase I trial in 2015

Leora Fox on November 04, 2014

A new clinical trial just announced for 2015 aims to test a “huntingtin lowering” therapy, called an antisense oligonucleotide (ASO), that attacks mutant huntingtin directly. We’re extremely excited—it’s the first-ever human HD trial to fight HD at the root of the problem, and has shown great promise in animal models. What’s the scoop?

Largest creatine clinical trial for Huntington's disease halted after 'futility' analysis

Largest creatine clinical trial for Huntington's disease halted after 'futility' analysis

Dr Ed Wild on October 29, 2014

CREST-E, the largest clinical trial of the dietary supplement creatine, has been terminated early because an early analysis of the results to date showed there was no realistic chance it could show positive results. This provides compelling evidence that creatine doesn't slow down progression in Huntington's disease patients.

EuroBuzz 2014: day three

EuroBuzz 2014: day three

Dr Ed Wild on September 21, 2014

Our final report from the European HD Network meeting. For the first time, video of many presentations, including our 'EuroBuzz' sessions will be made available online shortly.

EuroBuzz 2014: day two

EuroBuzz 2014: day two

Dr Jeff Carroll on September 20, 2014

Here's Ed and Jeff's live Twitter report from the second day of the EHDN 2014 meeting. Our final report will be tomorrow, and we'll be uploading video of our onstage roundup sessions soon.

EuroBuzz 2014: day one

EuroBuzz 2014: day one

Dr Ed Wild on September 19, 2014

Join Jeff and Ed as we tweet live from the 2014 European Huntington's Disease Network meeting in Barcelona! Exciting science ahead!

2CARE study of coenzyme Q for Huntington's disease ends in disappointment

2CARE study of coenzyme Q for Huntington's disease ends in disappointment

Dr Jeff Carroll on August 13, 2014

The largest ever therapeutic trial for Huntington's disease was halted early this week because an analysis of the results to date showed that it was very unlikely to show positive results. The study, called 2CARE, was designed to test whether a treatment called coenzyme Q10 could slow the progression of HD.

The brain in Huntington's disease: greater than the sum of its parts?

The brain in Huntington's disease: greater than the sum of its parts?

Dr Jeff Carroll on May 19, 2014

The symptoms of HD are caused by damage to the brain, but not all parts of the brain are affected equally. This raises an important question - if we had a treatment that could help only a small part of the brain, which part would we pick? A new mouse study from William Yang, at UCLA, attempts to answer this question.